{"id":"NCT01591655","sponsor":"Bausch & Lomb Incorporated","briefTitle":"Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery","officialTitle":"The Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2013-09","completion":"2013-10","firstPosted":"2012-05-04","resultsPosted":"2020-09-03","lastUpdate":"2020-09-03"},"enrollment":360,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Cataract","Inflammation","Surgery"],"interventions":[{"type":"DRUG","name":"Mapracorat","otherNames":[]},{"type":"DRUG","name":"Vehicle","otherNames":[]}],"arms":[{"label":"Mapracorat","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this clinical study is to compare the safety and efficacy of mapracorat ophthalmic suspension, 3% with its vehicle for the treatment of postoperative inflammation and pain following cataract surgery. Participants from the United States and Canada will be recruited for this study.","primaryOutcome":{"measure":"Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells","timeFrame":"8 days","effectByArm":[{"arm":"Mapracorat","deltaMin":38,"sd":null},{"arm":"Vehicle","deltaMin":13,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":240},"commonTop":["Eye pain"]}}